Available NCT07250737
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping
Sponsor: Avidity Biosciences, Inc.
Conditions
Genetic Diseases, Inborn Genetic Diseases, X-Linked Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Muscular Dystrophy, Duchenne Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases
Interventions
delpacibart zotadirsen
Updated 2 times since 2025 Last updated: Feb 23, 2026
A observational or N/A phase clinical study on Genetic Diseases, Inborn and Genetic Diseases, X-Linked, this trial is ongoing. The trial is conducted by Avidity Biosciences, Inc. and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Feb 2026 — Present [monthly]
Available
-
Dec 2025 — Feb 2026 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Avidity Biosciences, Inc.
- Clinigen Healthcare Limited
Data source: Avidity Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .